Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South Africa.
J Antimicrob Chemother. 2012 Feb;67(2):290-8. doi: 10.1093/jac/dkr444. Epub 2011 Oct 20.
Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-inflammatory activities. However, its efficacy has been demonstrated only in the treatment of leprosy, not in human tuberculosis, despite the fact that this agent is impressively active in vitro against multidrug-resistant strains of Mycobacterium tuberculosis. Recent insights into novel targets and mechanisms of antimicrobial and anti-inflammatory activity coupled with the acquisition of innovative drug delivery technologies have, however, rekindled interest in clofazimine as a potential therapy for multidrug- and extensively multidrug-resistant tuberculosis in particular, as well as several autoimmune diseases. The primary objective of this review is to critically evaluate these recent developments and to assess their potential impact on improving the therapeutic efficacy and versatility of clofazimine.
氯法齐明是一种亲脂性的利福平吩嗪抗生素，具有抗分枝杆菌和抗炎活性。然而，尽管该药物在体外对耐多药结核分枝杆菌具有显著的活性，但它仅在治疗麻风病方面显示出疗效，而不是在人类结核病方面。最近对抗微生物和抗炎活性的新靶点和机制的深入了解，以及创新药物输送技术的获得，重新激起了人们对氯法齐明作为治疗耐多药和广泛耐药结核病，特别是几种自身免疫性疾病的潜在疗法的兴趣。本综述的主要目的是批判性地评估这些最新进展，并评估它们对提高氯法齐明治疗效果和多功能性的潜在影响。
